Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C - Wikidata - wikimedia - TriplyDB

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

http://www.wikidata.org/entity/Q34134940

about

Aging and liver disease Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C.Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens.Treatment Response and Tolerability of Pegylated Interferon-α Plus Ribavirin Combination Therapy in elderly Patients (≥ 65 years) With Chronic Hepatitis C in Korea.Analysis of renal function during telaprevir-based triple therapy for chronic hepatitis C Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection Predictors for dose reduction of antiviral therapy in older patients infected with hepatitis C virus: a meta-regression analysis.Chronic hepatitis C in the aged: much ado about nothing or nothing to do?Treating hepatitis C in the elderly: the future is near?Optimal management of patients with chronic hepatitis C and comorbidities.Hepatitis C Infection in the Elderly.Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1.Interferon- α -Induced Changes to Natural Killer Cells Are Associated with the Treatment Outcomes in Patients with HCV Infections.Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy.Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.Occurrence of hepatocellular carcinoma was not a rare event during and immediately after antiviral treatment in Japanese HCV-positive patients.Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.Occurrence of clinical depression during combination therapy with pegylated interferon alpha or natural human interferon beta plus ribavirin.Impact of ribavirin dose reduction on the efficacy of pegylated interferon plus ribavirin combination therapy for elderly patients infected with genotype 1b and high viral loads.Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase.

P2860

Q26852595-AF9DC316-17A5-48C8-A783-A9F153756F15 Q33948241-9B6198D8-3294-4C44-8C69-AE74E8C58F45 Q35783876-ADB3CB05-3CF9-4D34-B966-C1E9BC8F93ED Q36220201-F7653197-13AB-4A0A-AD87-F76011FC7AC3 Q36824924-F23F07A2-7156-413D-AE5F-317EAAFC5825 Q37130025-22EE2767-2F9C-417C-BB5D-03AA459C20B9 Q38160178-5A0DD96E-E4D1-4459-BBE6-E9457974DEFD Q38198992-4078267E-2950-416D-925F-3E638094D4BD Q38243001-80A7BA62-6764-4BA9-A80D-9D585D510BAD Q38295819-C4104BFF-CA42-4D8E-AF90-09469FFFB3C5 Q38501726-DFFCA602-3ACD-43B0-83C4-105C701925B6 Q40707649-0718C2BA-6190-45DB-AD79-CC8F712DF5CA Q42119090-9BE42C33-6610-46BD-8C03-CB06ED3B02A4 Q42247557-82C4CA4A-3D05-4EFD-A5BE-9ACB1303EAE2 Q42980055-6072EA0F-16B3-468F-ABB0-F1ECECFBBD10 Q43036190-FEB72CF6-8A7B-46FD-9B59-F157E225AC0C Q43039523-BBFE9749-A57F-4BB9-975C-A786D816141C Q43042527-DF841911-D8B5-4D1D-9315-33F9C92A6EB5 Q48269156-A88FC1E7-BE7B-4736-8099-C204D0B5D584 Q50530986-F41CB598-1BAD-4D9D-8216-FFC2756B3BEF Q50550604-2F1600AF-6ECD-46DE-854E-089F5C8C05E3 Q50551487-6B85C4DA-5358-4B8C-A7DF-85834FD58A9E Q50554397-9DCE22A0-4DE5-403B-B8A6-2539B458F72D

P2860

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

http://www.wikidata.org/entity/Q34134940

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

@ast

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

@en

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

@nl

type

label

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

@ast

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

@en

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

@nl

prefLabel

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

@ast

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

@en

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

@nl

P1433

Q34134940-D2B4DC0D-FAE8-4161-B787-D4DDF6727823

P1476

Q34134940-5E655883-7045-48DD-A838-FB1471348385

P2093

Q34134940-1B975B14-64DC-4954-B22E-6875B650B42A

Q34134940-2C951B80-CE16-4755-8BCA-F4922FF85CF5

Q34134940-4E0154AE-784E-4823-ACE0-2E9CE4FF1A62

Q34134940-658CB4FD-4D45-4FA2-B15B-3C36167CDB3D

Q34134940-74365312-ECB1-4BA9-800A-1AD45131534C

Q34134940-7C084ED5-28E8-43B1-B741-ECF72A0FCA5A

Q34134940-7F9904CE-C266-439D-935D-2B2A027D9273

Q34134940-8C893006-106C-45F5-B7D9-CF4BBD58506B

Q34134940-9826B181-BC17-42F6-90F7-C8A47BECBBD2

Q34134940-AA7CEEE4-9B08-481F-B250-8E717986BCE8

P2860

Q34134940-06FEA627-9894-479C-91AA-6A851F6BEE3E

Q34134940-0B1E5CBE-DC78-4A19-B418-79F30DCF6E54

Q34134940-0ECF02FF-67C2-496A-B965-E8B6CF781F3F

Q34134940-121995F5-3F84-4522-ADBA-BDEAD86D9865

Q34134940-24A941B7-3C82-4741-96CB-85E95F33FA92

Q34134940-2734569F-48D0-45C9-8CBF-9771DE52EFE3

Q34134940-33A2628F-A836-4999-A26C-28DB7EBE9B2E

Q34134940-40A87C97-1801-4385-B1BD-DE0B7B281E43

Q34134940-491B6B7D-FD56-448E-A38C-8D56316E2EBF

Q34134940-4B3E08F0-AC4C-47FA-8159-CB0BA52A896C

P304

Q34134940-28E6B948-6307-4A86-9B8C-5BC3AB695986

P31

Q34134940-96CEF81F-1819-40E4-8314-6210FD72E11D

P356

Q34134940-27E3F3B9-E0B4-4C48-8E01-360437793CAC

P407

Q34134940-0507A377-85A5-45C6-8B96-55364BF5538A

P433

Q34134940-249861F7-5E4C-458C-ABCE-1379BAB92733

P478

Q34134940-B7358693-C6E8-4431-8F02-FFEDDA22144A

P577

Q34134940-0C32D5B8-0A18-4614-8203-D5F966DD125A

P698

Q34134940-F986FF9E-6769-460B-87AB-68802B3C4175

P932

Q34134940-99CEA5D8-CAE4-4FCE-A67F-1DDBA209D1E7

P356

WJG.V16.I35.4400

P1433

World Journal of Gastroenterology

P1476

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

@en

P2093

Eiji Kajiwara

http://www.w3.org/2001/XMLSchema#string

Hideyuki Nomura

http://www.w3.org/2001/XMLSchema#string

Jun Hayashi

http://www.w3.org/2001/XMLSchema#string

Junya Shimono

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Kotoh

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Takahashi

http://www.w3.org/2001/XMLSchema#string

Koichi Azuma

http://www.w3.org/2001/XMLSchema#string

Kyushu University Liver Disease Study Group

http://www.w3.org/2001/XMLSchema#string

Makoto Nakamuta

http://www.w3.org/2001/XMLSchema#string

Mosaburo Kainuma

http://www.w3.org/2001/XMLSchema#string

P2860

A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Hepatitis C virus infection

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.

Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis.

Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group

Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C.

P304

4400-4409

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V16.I35.4400

http://www.w3.org/2001/XMLSchema#string

P407

P433

35

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20845506

http://www.w3.org/2001/XMLSchema#string

P932

2941062

http://www.w3.org/2001/XMLSchema#string